At City Fertility we believe our strong focus on research allows us to provide our patients with the best chance of having a baby.
City Fertility are part of a research project with the University of New South Wales.
We are currently recruiting patients interested in taking part in the trial at our Sydney CBD clinic.
To participate you must be 21-42 years old, with a body mass index (BMI) between 18-35, located in Sydney and you also meet one of the following criteria:
Approximately 10% of women undergoing COS produce an unexpectedly sub-optimal number of oocytes (eggs). There is an unmet need for a better approach to treating this group of women.
The Elonva Flare Protocol (EFP) may be a new approach to this issue. Elonva is a long-acting type of FSH hormone. It is possible that Elonva when combined with a short agonist flare cycle, may improve FSH exposure leading to a higher oocyte yield. EFP also involves fewer injections when compared with antagonist or long down-regulation (LDR) cycles, which may be attractive to patients.
We will compare the hormone levels seen with the Elonva flare protocol with the levels in an Elonva antagonist cycle. If you agree to take part, then you would be randomly allocated to follow one of these two protocols. Importantly, both arms of the study use the Elonva long acting FSH. All other aspects of your IVF cycle would follow a standard approach.
The study aims to evaluate IVF laboratory and clinical outcomes including hormone levels, egg yield, fertilisation rate, embryo development, pregnancy and live birth rates.